BioLineRx Announces That Two Abstracts Featuring GLIX1 Will Be Presented At The Society For Neuro-Oncology Annual Meeting, November 12-15
The presentations will highlight preclinical research evaluating GLIX1 across multiple glioblastoma models, as well as the design of the ongoing Phase 1/2a clinical trial evaluating GLIX1 in patients with recurrent or
BioLineRx is showing early research on a new cancer medicine called GLIX1. Scientists will present their findings at a big medical conference, which gives the company a chance to share progress.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.